High-Grade Serous Carcinoma of the Ovary, Fallopian Tube, and Peritoneum

What High-Grade Serous Carcinoma Is, and Where It Sits in Classification

High-grade serous carcinoma (HGSC) is the most common and the most lethal ovarian carcinoma, and in the 5th edition of the WHO classification it is a firmly recognized subtype within the serous tumour family [1]. That family also contains low-grade serous carcinoma (LGSC) — and one of the more important conceptual shifts of the past two decades is that HGSC and LGSC are not two ends of a grading spectrum. They are separate diseases with separate biology, different precursor lesions, and different molecular drivers. Calling something "grade 3 serous carcinoma" as though it were simply a worse version of a grade 1 tumour is a framing the field has moved past.

The other reorientation worth stating up front is anatomic. Much of what we historically called "ovarian" HGSC in fact begins in the distal fallopian tube. The recognized precursor is serous tubal intraepithelial carcinoma (STIC), and the tubal-origin model now underlies how these tumours are conceptualized as an ovarian–tubal–peritoneal group rather than an ovarian entity alone [1].

How a Pathologist Recognizes High-Grade Serous Carcinoma

The diagnostic sequence runs morphology → immunohistochemistry → molecular, in that order, and each step earns its place.

Morphology first. HGSC grows in papillary, solid, and glandular architecture, often intermixed within a single tumour. The nuclei are the anchor of the diagnosis: they are markedly atypical, pleomorphic, and hyperchromatic, with a brisk mitotic rate and frequent atypical mitoses. Psammoma bodies — laminated calcifications — are a characteristic accompaniment, though they're neither required nor specific. When a sampled fallopian tube shows STIC, that finding supports tubal origin and reinforces the diagnosis [1].

Immunohistochemistry second. The defining immunoprofile is WT1 positivity paired with an aberrant (mutant-pattern) p53 result. WT1 places the tumour in the serous lineage; PAX8 confirms Müllerian origin. The p53 stain deserves careful reading because "aberrant" has two faces. One is diffuse strong overexpression — the pattern trainees expect. The other is complete absence of staining, the so-called null pattern, which reflects a truncating or nonsense TP53 mutation that yields no detectable protein. Both are abnormal; both point to the same underlying event. In practice the null pattern catches trainees off guard more often than overexpression does, because an entirely blank tumour reads as "negative" until you remember that a properly staining internal control makes absence itself the abnormal finding. Don't confuse a null result with a failed stain. p16 shows block-positive (diffuse) expression, adding supportive weight [1].

Molecular last, and confirmatory. HGSC carries near-universal TP53 mutation — this is the molecular signature of the entity, and it's why the aberrant p53 immunostain is such a reliable surrogate. A large subset also harbours BRCA1/2 mutation or broader homologous-recombination deficiency (HRD) [1]. Molecular testing here is not usually about establishing the diagnosis, which morphology and IHC generally settle; it's about characterizing the tumour further, including features relevant to systemic-therapy eligibility.

Grading and Classification: Why HGSC and LGSC Are Distinct Entities

Serous carcinoma of the ovary and tube is graded on a binary system: high-grade or low-grade. HGSC is, by definition, high-grade — there is no low-grade variant of it, and no three-tier scheme is applied [1]. The binary approach exists precisely because the older continuous grading implied a biological progression that does not hold.

Consider what separates the two entities at the molecular level. HGSC is defined by TP53 mutation and, in a substantial fraction of cases, by BRCA1/2 alteration or wider homologous-recombination deficiency [1]. LGSC follows a different route entirely, driven through the MAPK signalling pathway with recurrent mutations such as KRAS and BRAF, and it characteristically retains wild-type TP53. These are not quantitative differences in aggressiveness; they are qualitatively different oncogenic programs. That's why a low-grade serous carcinoma does not, in the ordinary course, transform into a high-grade one — the two arise from different molecular soil. The immunophenotype tracks this divergence: an aberrant p53 result argues strongly for HGSC, whereas a wild-type (normal, patchy) p53 pattern in a serous tumour with low-grade nuclei points toward LGSC. Reading the two as points on one grading line misrepresents both the biology and the expected clinical course, which is why the WHO framework treats them as separate diagnoses rather than tiers of a single tumour [1].

Why the Distinction Matters Clinically

The stakes of this distinction are practical. HGSC is the dominant cause of ovarian cancer mortality, so accurate identification carries real weight for prognosis and management [1]. The WT1-positive, aberrant-p53 immunoprofile is what allows a confident diagnosis on limited material, and that diagnosis in turn sets the stage for the molecular workup.

The HRD and BRCA1/2 findings are where pathology connects to systemic therapy. A large subset of HGSC shows homologous-recombination deficiency, and this molecular feature is what establishes eligibility for the PARP-inhibitor class of agents [1]. It's worth being precise about scope here: the pathologist and the molecular report define the tumour's biology and flag the relevant status. Whether and how a given drug class is used is a decision for the treating clinical team, made in the context of the whole patient. The report's job is to say clearly what the tumour is and what its molecular characteristics are.

A well-constructed HGSC report should therefore convey three things to the clinical team: an unambiguous morphologic and immunophenotypic diagnosis, the p53 pattern that supports it (specifying overexpression versus null), and the BRCA1/2 and HRD status once resolved. Those elements, taken together, tell the oncologist not just what the tumour is called but how it is likely to behave and which therapeutic avenues merit consideration.

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.